Free tool
FAERS Monitor: Lumigan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022184 or its brand name (Lumigan, Bimatoprost). Reports on generic versions are filed under their own applications.
Reports
19,414
Serious
7,523
39% of reports
Hospitalization
3,122
Death reported
798
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure3,080
- drug ineffective1,931
- ocular hyperaemia951
- eye irritation925
- fatigue708
- eye pain681
- intraocular pressure increased662
- vision blurred617
- hypersensitivity580
- headache574
- off label use559
- dyspnoea546
- diarrhoea519
- dizziness514
- nausea501
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 101 |
| 2005 | 73 |
| 2006 | 102 |
| 2007 | 129 |
| 2008 | 139 |
| 2009 | 247 |
| 2010 | 290 |
| 2011 | 398 |
| 2012 | 641 |
| 2013 | 561 |
| 2014 | 616 |
| 2015 | 1,274 |
| 2016 | 1,481 |
| 2017 | 1,423 |
| 2018 | 1,091 |
| 2019 | 1,238 |
| 2020 | 3,926 |
| 2021 | 2,062 |
| 2022 | 781 |
| 2023 | 847 |
| 2024 | 678 |
| 2025 | 743 |
| 2026 | 573 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,745 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 662 | 59.1 | 54.7 | 35,838 |
| treatment failureSignal | 3,080 | 41.8 | 40.4 | 118,510 |
| ocular hyperaemiaSignal | 951 | 22.1 | 20.8 | 18,827 |
| eye irritationSignal | 925 | 17.7 | 16.6 | 14,344 |
| eye painSignal | 681 | 13.2 | 12.3 | 7,611 |
| vision blurredSignal | 617 | 4.9 | 4.5 | 1,907 |
| hypersensitivitySignal | 580 | 3.4 | 3.1 | 982 |
| drug ineffective | 1,931 | 1.6 | 1.5 | 448 |
| dizziness | 514 | 1.1 | 1.0 | 6 |
| dyspnoea | 546 | 1.0 | 1.0 | 1 |
| headache | 574 | 1.0 | 0.9 | 0 |
| fatigue | 708 | 1.0 | 0.9 | 0 |
| diarrhoea | 519 | 0.9 | 0.8 | 10 |
| off label use | 559 | 0.7 | 0.6 | 80 |
| nausea | 501 | 0.7 | 0.6 | 75 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.